Depatuxizumab

Cat. No.:	HY-P99849
CAS No.:	1471999-69-5
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer[1].

In Vivo

Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth significantly in U87MGde2-7 glioblastoma multiforme (GBM) models and A431 squamous xenograft models of Nu/Nu mice[1].
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth and pEGFR levels in EGFRvIII-positive GBM SN0199 PDX models of NSG mice[1].
Depatuxizumab (2-40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth with dose dependent manner in SCC15 xenograft models of SCID Beige mice[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1]
Dosage:	10, 40 mg/kg, three times a week for 2 weeks
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited tumor growth significantly more than Cetuximab (HY-P9905). Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).

Animal Model:	EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm^3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1]
Dosage:	10, 40 mg/kg, three times a week for 2 weeks
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited tumor growth significantly and reduced levels of pEGFR.

Animal Model:	A431 squamous xenograft model of Nu/Nu mice[1]

Dosage:	10, 40 mg/kg, three times a week for 2 weeks
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg. Inhibited tumor growth by 58% at 40 mg/kg.

Animal Model:	SCC15 xenograft model of SCID Beige mice[1]
Dosage:	2, 10, 20, 40 mg/kg, three times a week for 2 weeks
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited tumor growth with dose manner. Reduced the level of pEGFR and total EGFR in time-dependent. Reduced cell proliferation as measured by phospho-histone H3. Increased apoptosis as measured by caspase-3 cleavage. Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.

REFERENCES

[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA